Chemokine Receptor 5 Has No Major Role in the Severity of Hepatitis C Virus-Related Liver Damage

Giuseppe Colucci, Roberta D'Ambrosio, Enrico Galmozzi, Marco Maggioni, Stella De Nicola, Alessio Aghemo, Massimo Colombo

Research output: Contribution to journalArticle

Abstract

Total or partial inactivation of the chemokine 5 (CC5) pathway, as caused by the CC5 receptor Δ32 deletion (CCR5Δ32), may result in a profound manipulation of immune surveillance with significant consequences on the course and response to therapy of diverse human infections, including HIV. It has been postulated that in chronic hepatitis C (CHC), such a deregulation of CC5 pathway may compromise T cell-dependent antiviral immune responses, which in turn may favor viral persistence. To test this hypothesis, we investigated a cohort of 100 patients with CHC in whom 12 heterozygous and 1 homozygous CCR5Δ32 mutations were detected compared to 8 and none in 98 healthy controls (13% vs. 8.2%, p = 0.36). As patients with and without CCR5Δ32 mutations were similar in terms of histological activity (p = 0.84) and fibrosis stage (p = 0.20) as well as CCR5 tissue expression, we reasonably exclude that this CCR5 mutation is significantly involved in the pathogenesis of CHC and may be a potential therapeutic target. However, deleted patients showed a significantly higher response to pegylated interferon-alfa (PEG-IFN), suggesting that a dormant immune system is more readily primed by immunostimulation.

Original languageEnglish
Pages (from-to)358-361
Number of pages4
JournalViral Immunology
Volume31
Issue number5
DOIs
Publication statusPublished - Jun 1 2018

Fingerprint

Chemokine Receptors
Chronic Hepatitis C
Hepacivirus
Mutation
Liver
Chemokines
Interferon-alpha
HIV Infections
Antiviral Agents
Immune System
Immunization
Fibrosis
T-Lymphocytes
Therapeutics

Keywords

  • CCR5
  • CCR5D32
  • Chronic hepatitis C
  • histological grade
  • histological stage

ASJC Scopus subject areas

  • Immunology
  • Molecular Medicine
  • Virology

Cite this

Chemokine Receptor 5 Has No Major Role in the Severity of Hepatitis C Virus-Related Liver Damage. / Colucci, Giuseppe; D'Ambrosio, Roberta; Galmozzi, Enrico; Maggioni, Marco; De Nicola, Stella; Aghemo, Alessio; Colombo, Massimo.

In: Viral Immunology, Vol. 31, No. 5, 01.06.2018, p. 358-361.

Research output: Contribution to journalArticle

@article{aeeeea6b97544e46bfd75addb303a964,
title = "Chemokine Receptor 5 Has No Major Role in the Severity of Hepatitis C Virus-Related Liver Damage",
abstract = "Total or partial inactivation of the chemokine 5 (CC5) pathway, as caused by the CC5 receptor Δ32 deletion (CCR5Δ32), may result in a profound manipulation of immune surveillance with significant consequences on the course and response to therapy of diverse human infections, including HIV. It has been postulated that in chronic hepatitis C (CHC), such a deregulation of CC5 pathway may compromise T cell-dependent antiviral immune responses, which in turn may favor viral persistence. To test this hypothesis, we investigated a cohort of 100 patients with CHC in whom 12 heterozygous and 1 homozygous CCR5Δ32 mutations were detected compared to 8 and none in 98 healthy controls (13{\%} vs. 8.2{\%}, p = 0.36). As patients with and without CCR5Δ32 mutations were similar in terms of histological activity (p = 0.84) and fibrosis stage (p = 0.20) as well as CCR5 tissue expression, we reasonably exclude that this CCR5 mutation is significantly involved in the pathogenesis of CHC and may be a potential therapeutic target. However, deleted patients showed a significantly higher response to pegylated interferon-alfa (PEG-IFN), suggesting that a dormant immune system is more readily primed by immunostimulation.",
keywords = "CCR5, CCR5D32, Chronic hepatitis C, histological grade, histological stage",
author = "Giuseppe Colucci and Roberta D'Ambrosio and Enrico Galmozzi and Marco Maggioni and {De Nicola}, Stella and Alessio Aghemo and Massimo Colombo",
year = "2018",
month = "6",
day = "1",
doi = "10.1089/vim.2017.0190",
language = "English",
volume = "31",
pages = "358--361",
journal = "Viral Immunology",
issn = "0882-8245",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

TY - JOUR

T1 - Chemokine Receptor 5 Has No Major Role in the Severity of Hepatitis C Virus-Related Liver Damage

AU - Colucci, Giuseppe

AU - D'Ambrosio, Roberta

AU - Galmozzi, Enrico

AU - Maggioni, Marco

AU - De Nicola, Stella

AU - Aghemo, Alessio

AU - Colombo, Massimo

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Total or partial inactivation of the chemokine 5 (CC5) pathway, as caused by the CC5 receptor Δ32 deletion (CCR5Δ32), may result in a profound manipulation of immune surveillance with significant consequences on the course and response to therapy of diverse human infections, including HIV. It has been postulated that in chronic hepatitis C (CHC), such a deregulation of CC5 pathway may compromise T cell-dependent antiviral immune responses, which in turn may favor viral persistence. To test this hypothesis, we investigated a cohort of 100 patients with CHC in whom 12 heterozygous and 1 homozygous CCR5Δ32 mutations were detected compared to 8 and none in 98 healthy controls (13% vs. 8.2%, p = 0.36). As patients with and without CCR5Δ32 mutations were similar in terms of histological activity (p = 0.84) and fibrosis stage (p = 0.20) as well as CCR5 tissue expression, we reasonably exclude that this CCR5 mutation is significantly involved in the pathogenesis of CHC and may be a potential therapeutic target. However, deleted patients showed a significantly higher response to pegylated interferon-alfa (PEG-IFN), suggesting that a dormant immune system is more readily primed by immunostimulation.

AB - Total or partial inactivation of the chemokine 5 (CC5) pathway, as caused by the CC5 receptor Δ32 deletion (CCR5Δ32), may result in a profound manipulation of immune surveillance with significant consequences on the course and response to therapy of diverse human infections, including HIV. It has been postulated that in chronic hepatitis C (CHC), such a deregulation of CC5 pathway may compromise T cell-dependent antiviral immune responses, which in turn may favor viral persistence. To test this hypothesis, we investigated a cohort of 100 patients with CHC in whom 12 heterozygous and 1 homozygous CCR5Δ32 mutations were detected compared to 8 and none in 98 healthy controls (13% vs. 8.2%, p = 0.36). As patients with and without CCR5Δ32 mutations were similar in terms of histological activity (p = 0.84) and fibrosis stage (p = 0.20) as well as CCR5 tissue expression, we reasonably exclude that this CCR5 mutation is significantly involved in the pathogenesis of CHC and may be a potential therapeutic target. However, deleted patients showed a significantly higher response to pegylated interferon-alfa (PEG-IFN), suggesting that a dormant immune system is more readily primed by immunostimulation.

KW - CCR5

KW - CCR5D32

KW - Chronic hepatitis C

KW - histological grade

KW - histological stage

UR - http://www.scopus.com/inward/record.url?scp=85048343653&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048343653&partnerID=8YFLogxK

U2 - 10.1089/vim.2017.0190

DO - 10.1089/vim.2017.0190

M3 - Article

AN - SCOPUS:85048343653

VL - 31

SP - 358

EP - 361

JO - Viral Immunology

JF - Viral Immunology

SN - 0882-8245

IS - 5

ER -